Q
Q-State Biosciences
Comprehensive genomic services ranging from genetic sequencing to mutation modelling and screening to targeted antisense oligonucleotide (ASO) design
About Q-State Biosciences
Q State Biosciences is a precision medicine company focused on developing genetically targeted treatments for patients suffering from nervous system disorders. Operating in the biotechnology sector, the company leverages its proprietary ResQueTM Platform, which integrates advanced technologies to map individual genomes to specific genetic therapies. This approach allows Q State Biosciences to identify and deliver transformative treatments more quickly and accurately than traditional methods. The company primarily serves patients with devastating genetic disorders, aiming to address the root causes of these diseases. Q State Biosciences generates revenue through the development and commercialization of its therapeutic candidates. The company also has a history of spinning out specialized entities, such as QurAlis and Enclear Therapies, which focus on ALS treatments. The business model is centered around innovation in genetic therapy, targeting unmet medical needs in the neurological space.
Source: Dealroom company dataNews
Open roles
Q-State Biosciences in the Cambridge ecosystem
The Q-State Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Q-State Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Q-State Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


